- Home
- About
- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- IgAN
- Events
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefR
- Radiology Toolkit
- On Demand Webinars
- Infographics
- Podcasts
- Videos
- Request a Presentation
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
IgA Nephropathy – From Pathogenesis To Current Management
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
IgA Nephropathy – From Pathogenesis To Current Management
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression.
Featuring
Molly Jansen, PhD
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*Dr Molly Jansen is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. covering South Texas. Molly earned her Doctor of Philosophy degree in Biomedical Science from Wake Forest School of Medicine located in Winston-Salem, NC. While in graduate school, Molly worked as a Business Development Intern at Wake Forest Innovations, fostering the collaborative innovation between industry and the faculty and staff of Wake Forest Baptist Medical Center. After graduate school, Molly did a brief Medical Writing Fellowship with Impact Pharmaceutical Services. Prior to joining Otsuka, Molly worked at Reata Pharmaceuticals, Inc. where she helped to oversee the conduct of clinical trials across a variety of therapeutic areas including nephrology, neurology, and pulmonary, which is where she developed her passion for rare disease.
*Dr Jansen is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).
Registration
Related Resources
-
Understanding the Benefits & Risks of Corticosteroid Use in Patients With IgAN
Infographic January 23, 2025This infographic highlights clinical trial results showing mixed efficacy and increased adverse events in patients with IgAN treated with corticosteroids.
-
Updates in IgA Nephropathy
Video January 14, 2025 -
On-Demand Webinar: The Four-Hit Hypothesis & The Role Of APRIL In IgA Nephropathy
On-Demand Webinar December 20, 2024 -
Breakdown of the MEST-C Score in IgA Nephropathy
Audio/Podcast November 12, 2024
Join Today for Instant Access to all NephU Offerings.
Membership is free!
Join NephU today at no cost to register for this event and access to other premium content.
- The NephU Community is collaborating to improve care and the future outcomes for individuals with kidney disease and other related conditions.
- Quickly learn more about the topics that interest you.
- Access our library of on-demand kidney health resources
- Gain key insights from industry experts & though leaders.
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.